Mitochondrial Dysfunction and NAD Supplementation: Why the Solution Isn't So Simple
Mitochondrial dysfunction is a central feature of aging, marked by both a decline in mitochondrial number and quality. This process is driven by several interconnected mechanisms: decreased mitochondrial formation, accumulation of genetic mutations, increased oxidative stress, accumulation of dysfunctional mitochondria, and morphological changes in which mitochondria become swollen, fragmented, and less able to maintain normal structure and function.
It would stand to reason that slowing or reversing this dysfunction could meaningfully hinder the process of aging. So what evidence exists for effective interventions? Despite mitochondrial health being something of a holy grail in anti-aging medicine, the evidence is — frankly — quite sparse.
Non-Pharmacologic Approaches
Exercise remains the most robustly supported intervention. Regular physical activity, especially high-intensity interval training and resistance training, stimulates mitochondrial biogenesis and improves mitochondrial function in older adults.
Caloric restriction, including through intermittent fasting, has consistently been shown to enhance mitochondrial function and reduce oxidative damage in both animal models and humans.
Dietary modifications rich in antioxidants and certain nutrients may support mitochondrial health, though the evidence is less robust than for exercise and caloric restriction.
Pharmacologic and Emerging Approaches
NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — have been shown in animal models to restore mitophagy, improve mitochondrial function, and extend healthspan. Human data is more limited, as discussed below.
Mitophagy activators targeting PINK1, Parkin, and USP30 pathways show promise in preclinical studies but are not yet commercially available.
PGC-1α activators that stimulate mitochondrial biogenesis are being explored, though most research remains preclinical.
Mitochondria-targeted peptides such as SS-31/elamipretide have shown efficacy in animal models and early human trials, improving mitochondrial function and reducing oxidative stress, but large-scale clinical outcome data remain limited.
Hormonal modulation also plays a role. Thyroid hormone, estrogen, and glucocorticoids influence mitochondrial biogenesis, and their decline with age may contribute to mitochondrial dysfunction. Hormone replacement therapy and treatment of metabolic disorders can therefore have indirect benefits.
NAD+ Supplementation: A Closer Look
Given its status as the most accessible therapeutic option currently available, NAD+ supplementation generates the highest volume of patient inquiries in my practice. Here is an honest review of what the evidence actually shows.
Oral NR and NMN
Both NR and NMN consistently increase blood NAD+ levels in healthy adults and older populations, with dose-dependent effects and generally good safety profiles. Short-term studies — typically 3 to 12 weeks — show good tolerability, with only mild side effects such as GI upset, rashes, and fatigue. NR is recognized as safe by the FDA and other regulatory agencies.
However, the clinical outcome data tells a more cautious story:
Some small trials show improvements in physical performance, muscle strength, insulin sensitivity (especially in overweight or prediabetic individuals), and cardiovascular and metabolic markers
Most studies in healthy individuals do not show significant improvements in clinical endpoints such as blood pressure, body weight, or metabolic health
Larger, well-powered trials are lacking — most published studies are small, short-term, and focus on surrogate markers or safety rather than hard clinical outcomes
Notable findings include improved muscle insulin signaling in overweight postmenopausal women with prediabetes, and some improvements in physical performance such as grip strength and walking distance in older adults — though these findings are not universal and need confirmation in larger trials.
IV and IM NAD+ Administration
This approach is far less studied than oral precursors. Only a handful of clinical trials have evaluated IV or IM NAD+ administration. In a small open-label trial of IV NADH in patients with chronic fatigue syndrome, approximately 62% showed significant improvement in disability — but there was no placebo control.
The pharmacokinetics are also unclear: IV NAD+ is likely rapidly degraded in the liver and bloodstream, and it is not well established how much reaches tissues intact. No large, well-controlled trials exist for IV or IM NAD+ in aging or chronic disease populations.
Long-term safety for both oral and parenteral NAD+ supplementation remains unknown. Some animal studies suggest high doses could impair glucose metabolism, though this has not been clearly demonstrated in humans.
The Bottom Line
Oral NR and NMN supplementation reliably increases NAD+ levels and is safe in the short term, with some evidence for clinical benefit in specific populations — particularly those with metabolic dysfunction or significant age-related decline. For healthy individuals, the evidence for meaningful clinical improvement is weak.
IV and IM NAD+ is less studied, with unclear pharmacokinetics and minimal clinical evidence to support its use.
Larger, longer, and well-controlled trials are needed to establish efficacy and safety for both routes — especially regarding meaningful clinical outcomes in aging populations. Until that data exists, the most evidence-based approaches to mitochondrial health remain the least glamorous: consistent exercise, adequate sleep, caloric balance, and managing metabolic risk factors.
References
Srivastava S. The Mitochondrial Basis of Aging and Age-Related Disorders. Genes (Basel). 2017;8(12):398.
Guo Y, et al. Mitochondrial dysfunction in aging. Ageing Research Reviews. 2023;88:101955.
Guo J, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy. 2022;7:391.
Duran J, Martinez A, Adler E. Mitochondrial Dysfunction in Aging and Diseases of Aging. Frontiers in Physiology. 2019.
Miwa S, Kashyap S, Chini E, von Zglinicki T. Mitochondrial dysfunction in cell senescence and aging. Journal of Clinical Investigation. 2022;132(13):e158447.
Kolhapur Institute of Technology's College of Engineering et al. Mitochondrial dysfunction and its association with age-related disorders. Frontiers in Physiology. 2024;15:1384966.
Dr. Schraga is a concierge physician at Crescendo MD in Portola Valley, California, specializing in preventive and longevity medicine for executives and families in Silicon Valley.
